VANCOUVER, BC and PRINCETON, NJ / ACCESSWIRE / September 27, 2022 / Xybion Digital Inc. (TSXV:XYBN) ('Xybion' or the 'Company'), a global, low-code SaaS company that enables digital transformation in highly regulated industries like Life Sciences, announced today that it has been awarded a multi-year, multi-million US dollar contract by a top five global pharmaceutical and healthcare products company headquartered in the USA whose products are sold in over 175 countries.
Xybion partnered with the global pharmaceutical company to standardize processes, streamline data, and simplify the R&D operating landscape through its business consulting work and deploying its preclinical R&D laboratory software, Pristima XD. This win further validates Xybion' s strategy of bringing end-to-end solutions for its clients to expedite research and development process and FDA approval so that new medicines can reach patients faster and save more lives. This pharmaceutical company selected Xybion for not only solving their current challenges, but also to work closely with Xybion to design additional software solutions that maximize lab digitization and simplify lab operations across various sites globally.
Dr. Pradip Banerjee, Chairman and CEO of Xybion Digital said 'We are proud to have been selected by this world-renowned pharmaceutical and healthcare products company as their partner for digital acceleration of R&D lab operations. Our end-to-end digital platform is ideally suited to help life sciences companies overcome the challenges of digital transformation. We look forward to helping this globally recognized pharmaceutical company achieve its goals.'
'We are very excited to start this partnership. Pristima XD preclinical solution creates an end-to-end digital laboratory execution environment with connected workflows, high automation, and data integrity for the entire preclinical operation. We are very excited to work with them to design additional solutions to further enhance lab digitization and automation capabilities of this client.' Said Kamal Biswas, President and COO at Xybion.
Pristima XD, is an all-in-one preclinical laboratory execution system that helps digitize lab operations, manage data, and improve productivity significantly. A library of preclinical software modules makes Pristima XD a unique lab management software that is comprehensive, unified, and all-in one.
Preclinical software modules include:
- Study Design
- Planning and Costing
- Protocol Management
- Study Management and Execution
- Animal Room
- Pathology and Digital Pathology
- Clinical Pathology
- Resource Management
- Colony Management
- Veterinary Management
- Master Schedule and Audits
- CAPA Management
- Employee Competency Management
About Xybion Digital Inc.
Xybion is a global SaaS company that helps enterprise life sciences organizations accelerate new drug development into approved medicines that may save lives and keep employees safe. We digitize drug research and development, laboratory testing, regulatory approvals, and pharmaceutical manufacturing on a single, unified cloud platform that is cost-effective, ready to deploy, and easy to use. Xybion has over 160 clients in 29 countries using its low-code software to accelerate timelines, improve compliance, expand capacity, minimize operating risks, and reduce expenses while keeping employees safe.
These modules are unified creating a robust lab execution system that provides seamless experience for all preclinical laboratory staff and a very simple IT ecosystem to maintain for the IT organization.
Learn more about Xybion at https://www.xybion.com/
For further information: For more information regarding Xybion Digital Inc., please contact Dr. Pradip K. Banerjee, Chairman & Chief Executive Officer, PBanerjee@xybion.com, 609-512-5790 x122
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Certain statements ('forward-looking statements') in this news release may contain forward-looking information concerning relating to Xybion's position in the life sciences sector, the services to be performed by Xybion as described above and the results thereof, plans related to the Company's business and other matters that may occur in the future, made as of the date of this news release. In making the forward-looking statements included in this news release, the Company has applied several material assumptions, including that Xybion will be able to perform its services as currently anticipated. Although management considers these assumptions to be reasonable based on information available to it, they may prove to be incorrect.
Forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors which could cause actual events or results to differ from those expressed or implied by the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important factors could cause the actual outcomes to differ materially from the expectations expressed in them. Such factors include, among others, the risk that the Company may not be able to perform its services as currently anticipated, that results of such services may not be consistent with anticipated outcomes, or those described in disclosure documents filed by the Company on SEDAR. There can be no assurance that forward-looking statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as otherwise required by applicable securities legislation.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the 'U.S. Securities Act'), or any state securities law and may not be offered or sold in the 'United States', as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.
SOURCE: Xybion Digital Inc.
View source version on accesswire.com: